| The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (NCT05131815) | Cedars-Sinai Medical Center | 2022-07-25 |
| Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma (NCT05490953) | University of Guadalajara | 2022-07-11 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| Involved Nodal Irradiation vs Involved Field Irradiation After Cth in Ttt of Early Stages HDs (NCT05284396) | Assiut University | 2022-05-01 |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (NCT04685616) | University College, London | 2022-04-14 |
| A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma (NCT05100056) | Takeda | 2022-03-08 |
| Investigating Cognitive Impairment in Young Patients With Cancer Prospectively (NCT05840575) | Rigshospitalet, Denmark | 2022-03-01 |
| Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study (NCT05169151) | M.D. Anderson Cancer Center | 2022-02-17 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma (NCT05208853) | Zhejiang University | 2022-02-10 |
| Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (NCT05253495) | New York Medical College | 2022-02-01 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors (NCT07259304) | University of Southern California | 2021-11-24 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-18 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma (NCT05019976) | University of Chicago | 2021-09-30 |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study (NCT05053100) | Mayo Clinic | 2021-08-17 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Lung Screening in People Cured of Hodgkin Lymphoma (NCT04986189) | The Christie NHS Foundation Trust | 2021-08-01 |
| Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events (NCT05123001) | Stanford University | 2021-07-15 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma (NCT04996862) | The Christie NHS Foundation Trust | 2021-06-01 |
| A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT (NCT04843267) | Sun Yat-sen University | 2021-05-01 |
| Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma. (NCT04621604) | Rennes University Hospital | 2021-04-12 |
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion (NCT04099966) | Mitchell Cairo | 2021-04-01 |
| Radiation Free Chemotherapy for Early Hodgkin Lymphoma (NCT04866654) | Medical University of Gdansk | 2021-03-04 |
| A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma (NCT04981899) | St. Petersburg State Pavlov Medical University | 2021-03-01 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies (NCT04748185) | Mayo Clinic | 2021-01-28 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers (NCT04072393) | Washington University School of Medicine | 2021-01-15 |
| Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma (NCT04893538) | Latakia University | 2021-01-04 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma (NCT04373083) | Regeneron Pharmaceuticals | 2020-11-15 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. (NCT04514081) | Chinese PLA General Hospital | 2020-08-01 |
| Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer (NCT04478123) | Memorial Sloan Kettering Cancer Center | 2020-07-14 |
| Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma (NCT04419441) | Ospedale Maggiore Di Trieste | 2020-06-24 |
| Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial (NCT05066555) | Fondazione Italiana Linfomi - ETS | 2020-04-08 |
| Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP) (NCT04091490) | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | 2020-02-19 |
| Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study (NCT04396119) | The Christie NHS Foundation Trust | 2020-02-11 |
| Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma (NCT04233294) | Chinese PLA General Hospital | 2020-02-02 |
| Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT04239170) | Peking University | 2020-01-01 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma (NCT03947255) | Seagen Inc. | 2019-10-28 |
| Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study (NCT03617666) | University College, London | 2019-09-27 |
| Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (NCT04510610) | Chinese PLA General Hospital | 2019-09-01 |
| Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma (NCT05660993) | National Research Center for Hematology, Russia | 2019-08-19 |
| Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen (NCT04026269) | Han weidong | 2019-07-30 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies (NCT04008394) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-07-03 |
| Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma (NCT03843294) | Catherine Bollard | 2019-06-24 |
| Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) (NCT03904134) | Center for International Blood and Marrow Transplant Research | 2019-06-14 |
| Improving Exercise Capacity With Tailored Physical Activity in Lymphoma & Breast Cancer Patients Undergoing Tx (NCT03923504) | Virginia Commonwealth University | 2019-05-10 |
| Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation (NCT03925935) | Angiocrine Bioscience | 2019-05-07 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies (NCT03885947) | Alla Keyzner | 2019-02-21 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning (NCT03852407) | University of Liege | 2019-02-04 |
| TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (NCT03849651) | St. Jude Children's Research Hospital | 2019-01-31 |
| Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma (NCT03646123) | Seagen Inc. | 2019-01-28 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma (NCT03602131) | Sichuan University | 2019-01-01 |
| Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma (NCT03730363) | Reinhold Munker | 2018-12-19 |
| Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (NCT03755804) | St. Jude Children's Research Hospital | 2018-12-12 |
| ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (NCT03337919) | University College, London | 2018-12-03 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma (NCT03331731) | Peter MacCallum Cancer Centre, Australia | 2018-11-29 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03739619) | Emory University | 2018-11-26 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS (NCT03495713) | Abramson Cancer Center at Penn Medicine | 2018-11-02 |
| Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03681561) | Veronika Bachanova | 2018-09-13 |
| Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma (NCT03580408) | The Lymphoma Academic Research Organisation | 2018-08-31 |
| Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma (NCT03302728) | Peter MacCallum Cancer Centre, Australia | 2018-08-30 |
| CBT on Fatigue in Survivors of Hodgkin Lymphoma (NCT03968250) | University of Leipzig | 2018-08-20 |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (NCT03560752) | City of Hope Medical Center | 2018-08-20 |
| BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL) (NCT03576378) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2018-08-08 |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma (NCT03618550) | Memorial Sloan Kettering Cancer Center | 2018-08-01 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (NCT03615105) | Memorial Sloan Kettering Cancer Center | 2018-07-25 |
| Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235) | Noah Merin | 2018-07-18 |
| Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk (NCT03436862) | SCRI Development Innovations, LLC | 2018-05-23 |
| A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma (NCT03505996) | CStone Pharmaceuticals | 2018-05-22 |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 (NCT02890758) | Brenda Cooper, MD | 2018-05-22 |
| Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (NCT03407144) | Merck Sharp & Dohme LLC | 2018-04-09 |
| CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma (NCT04726501) | Children's Cancer Group, China | 2018-04-01 |
| BV After Allogeneic Hematopoietic Stem Cell Transplantation (NCT03540849) | University Hospital, Caen | 2018-03-07 |
| Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma (NCT03664323) | Hospices Civils de Lyon | 2018-01-31 |
| OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy (NCT03527628) | King Abdullah International Medical Research Center | 2018-01-01 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| To Decrease Fatigue With Light Therapy (NCT03242902) | The Netherlands Cancer Institute | 2017-09-20 |
| SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma (NCT03250962) | Chinese PLA General Hospital | 2017-09-11 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT03192397) | Roswell Park Cancer Institute | 2017-08-09 |
| FIL Study on ABVD DD-DI as Upfront Therapy in HL. (NCT03159897) | Fondazione Italiana Linfomi - ETS | 2017-08-01 |
| ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma (NCT03107663) | ImaginAb, Inc. | 2017-06-19 |
| Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma (NCT03179917) | Memorial Sloan Kettering Cancer Center | 2017-06-08 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep (NCT02722668) | Masonic Cancer Center, University of Minnesota | 2017-05-15 |
| Auto Stem Cell Transplant for Lymphoma Patients (NCT03125642) | Masonic Cancer Center, University of Minnesota | 2017-04-20 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| Bergamo Lymphoid Cancer Registry (NCT03131531) | A.O. Ospedale Papa Giovanni XXIII | 2017-03-23 |